Login to Your Account

Merck’s HCV Regimen ‘C-Worthy’ in Early Test; Competitive Waters Ahead

By Jennifer Boggs
Managing Editor

Tuesday, November 5, 2013
With Gilead Sciences Inc. barely a month away from a possible history-making FDA approval of an all-oral regimen for hepatitis C virus (HCV), the American Association for the Study of Liver Diseases (AASLD) meeting in Washington put the spotlight on other HCV contenders over the weekend, with much of the buzz focused on a protease inhibitor/NS5A inhibitor combination from Merck & Co. Inc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription